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Bezlotoxumab for Prevention of Recurrent Clostridium 
difficile Infection.
M.H. Wilcox, D.N. Gerding, I.R. Poxton, C. Kelly,  
R. Nathan, T. Birch, O.A. Cornely, G. Rahav, E. Bouza, 
C. Lee, G. Jenkin, W. Jensen, Y.-S. Kim, J. Yoshida,  
L. Gabryelski, A. Pedley, K. Eves, R. Tipping, D. Guris, 
N. Kartsonis, M.-B. Dorr, for the MODIFY I  
and MODIFY II Investigators*.  
N Engl J Med 2017;376:305-317.
In high-income countries, Clostridioides difficile is the 
most common cause of infectious diarrhea among hospitalized 
patients. Approximately 35% of patients will suffer recurrent C. 
difficile infection, which is more difficult to treat and is related 
to more hospitalizations, more severe outcomes, and higher 
costs than the first infection. Actoxumab and bezlotoxumab 
are human monoclonal antibodies against C. difficile toxins A 
and B, respectively. Researchers conducted two double-blind 
phase 3 trials, MODIFY I and MODIFY II, involving 2655 
adults receiving oral antibiotics for primary or recurrent C. 
difficile infection. Participants received an infusion of bezlo-
toxumab (10 mg per kilogram of body weight), actoxumab 
plus bezlotoxumab (10 mg per kilogram each), or placebo; 
actoxumab alone (10 mg per kilogram) was given in MODIFY 
I. The primary end point was recurrent infection within 12 
weeks. In both trials, the rate of recurrent C. difficile infection 
was significantly lower with bezlotoxumab alone than with 
placebo (P<0.001). Bezlotoxumab was associated with a rate 
of recurrent infection that was 38% lower than that associated 
with standard-of-care antibiotics therapy alone. Actoxumab was 
not efficacious when given alone and provided no additional 
benefit when given with bezlotoxumab. These observations 
are consistent with evidence indicating that toxin B is the main 
virulent factor for recurrent C. difficile infection in humans. 
The rates of adverse events were similar among the groups; 
the most common adverse effects being diarrhea and nausea.
Among participants receiving antibiotic treatment for 
primary or recurrent Clostridioides difficile infection, be-
zlotoxumab was associated with a substantially lower rate 
of recurrent infection–especially among high risk patients 
for recurrent infection- than placebo and had a safety profile 
similar to that of placebo.
Clinical considerations for optimal use of the 
polymyxins: A focus on agent selection and dosing.
J.M. Pogue, J.K. Ortwine, K.S. Kaye. Clin Microbiol 
Infection 2017; 23:229-233.
Colistin (polymyxin E) and polymyxin B became com-
mercially available around the same time and their use has 
recently been increased, as they are effective for treating gram 
(-) multidrug resistant bacteria, such as carbapenem-resistant 
Enterobacteriaceae (Escherichia coli, Klebsiella pneumo-
niae, some Enterobacter spp), Pseudomonas aeruginosa, and 
Acinetobacter baumannii). While polymyxin B is available 
directly as its sulphate salt for intravenous administration 
(25,000 Units/Kg followed by 25,000 Units/Kg separated in 
two daily doses), colistin is only commercially available for 
intravenous use in the form of its inactive pro-drug, colistin 
methanesulphonate (CMS) -administered at a dose of 9,000,000 
international units initially and afterwards at a total dose of 
9,000,000 international units separated in two daily dosages-, 
which must be hydrolysed in vivo to active colistin. This differ-
ence in formulation results in pharmacokinetic differences in 
vivo. There are various advantages to polymyxin B in theory, 
which explain the trend towards increased use of this agent 
and decreased use of colistin in countries, where both products 
are available, such as the USA. These potential advantages 
of polymyxin B comprise a faster and more predictable peak 
concentration, a potential for decreased toxicity (nephrotoxic-
ity) as well as more predictable steady-state concentrations. 
Nevertheless, most of these advantages remain theoretical, and 
how polymyxin B performs compared with colistin remains 
largely unknown. Regarding its adverse side effects, there are 
reports of infusion-related reactions, peri-oral paraesthesias 
(neurotoxicity), and of skin hyperpigmentation with polymyxin 
B. Therefore, until further data become available, although 
it is reasonable to give preference to polymyxin B, colistin 
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should be considered a completely appropriate and acceptable 
alternative. Also, due to lack of evidence to support other for-
mulations, CMS remains the preferred agent for inhalational 
use. When CMS is used as inhalation therapy, it should be 
administered shortly after it is mixed. Furthermore, some 
researchers recommend CMS to be preferred for intrathecal/
intraventricular administration simply due to more experience 
and better applicable dosing recommendations.
New and improved? A review of novel antibiotics  
for Gram-positive bacteria.
M. Abbas, M. Paul, A. Huttner. Clin Microbiol Infection 
2017; 23:697-703.
MRSA infections together with VRE infections remain a 
siginificant problem among hospitalized patients. This review 
focuses on the new cephalosporins ceftaroline and ceftobi-
prole; the lipoglycopeptides dalbavancin, oritavancin and 
telavancin; the fluoroquinolones delafloxacin, nemonoxacin 
and zabofloxacin; and the tetracycline omadacycline. Named 
‘fifth-generation’ cephalosporins, ceftaroline and ceftobiprole 
are the first beta-lactams to possess anti-MRSA activity due to 
their high affinity for penicillin-binding protein-2a. Though both 
possess some activity against various Gram-negative pathogens, 
these drugs achieved approval for their anti-Gram-positive 
activity. Ceftaroline fosamil (Teflaro in the USA and Zinforo 
in Europe) achieved European Medicines Agency (EMA) 
approval in 2012. An inactive prodrug, ceftaroline fosamil, is 
rapidly converted in vivo to the active metabolite ceftaroline. 
They both appear to be well tolerated. Dalbavancin and ori-
tavancin are newly on the market but are not new drugs. Like 
vancomycin, they exert their bactericidal activity by binding 
to the D-alanyl-D-alanine residue on growing peptidoglycan 
chains, preventing transpeptidation and thus, cell wall forma-
tion [24]. Unlike vancomycin, these semi-synthetic molecules 
possess a lipid side-chain conferring new pharmacokinetic 
properties, such as high protein-binding and unusually long 
half-lives, which allow for single-dose therapy. They are 
active against MRSA, coagulase negative staphylococci, 
vancomycin-susceptible Enterococcus faecium, but not VRE. 
Dalbavancin and oritavancin were well-tolerated in clinical tri-
als. Tedizolid phosphate (Sivextro) is a synthetic oxazolidinone 
first developed in Korea in the 2000s and approved by FDA 
(2014) for the treatment of ABSSSI. Tedizolid inhibits protein 
synthesis by binding to the bacterial 50S ribosomal subunit. It 
is approved for a 6-days course treatment. Omadacycline is an 
aminomethylcycline antibiotic that possesses activity against a 
large series of Gram-positive and Gram-negative pathogens. It 
is bacteriostatic, inhibiting protein synthesis by binding to the 
30S ribosomal subunit. After all, we seem to possess newer 
drugs in our armamentarium against MRSA and VRE infections.
